A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT07029945 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Geographic Atrophy

Interventions

DRUG: BRX011
DRUG: Placebo

Sponsor

Biojiva LLC